Jensen Gert, Annerstedt Marita, Klingenstierna Hans, Herlitz Hans, Aurell Mattias, Hellström Mikael
Department of Nephrology, Sahlgrenska University Hospital, Göteborg, Sweden.
Scand J Urol Nephrol. 2009;43(3):236-41. doi: 10.1080/00365590902833606.
Renal percutaneous transluminal angioplasty (PTA) treatment of renal artery stenosis has been performed worldwide since 1978, but it is still a matter of debate as to what extent the patients benefit from the procedure in terms of quality of life and long-term survival.
Of 139 patients referred for renal angioplasty owing to hypertension or pending uraemia, 105 were subsequently treated with PTA. Eighty-eight patients survived for 5 years. Fifty-nine patients were re-examined according to a protocol including physical examination, blood pressure, drug therapy, glomerular filtration rate and quality of life assessment, and an additional 29 patients were interviewed by telephone regarding quality of life. PTA was not conducted in 34 patients owing to high risks as decided at joint radiology-nephrology conferences.
The 5-year survival was 83% for PTA-treated patients with arteriosclerotic renovascular disease, 100% for patients with fibromuscular vascular disease and 47% for the non-PTA-treated patients. The main causes of death were cardiovascular and cerebrovascular events in both groups. Reduced blood pressure and reduced need for antihypertensive drug treatment were observed in the PTA-treated patients. The renal function was stable. A majority of the PTA-treated patients stated that they had "unrestricted" physical activity, and the physical, mental and social well-being was self-rated as level 4-5 (mostly good and very good) on a five-grade scale by 53%, 67% and 75% of the patients, respectively, at the follow-up investigation. The untreated patients were not interviewed.
The study showed a high survival rate, improved blood pressure control and stable renal function 5 years after renal PTA, and a vast majority of the patients rated their physical, mental and social well-being favourably.
自1978年以来,肾动脉狭窄的经皮腔内血管成形术(PTA)已在全球范围内开展,但患者在生活质量和长期生存方面从该手术中获益的程度仍存在争议。
139例因高血压或即将发生尿毒症而转诊接受肾血管成形术的患者中,105例随后接受了PTA治疗。88例患者存活了5年。59例患者按照包括体格检查、血压、药物治疗、肾小球滤过率和生活质量评估的方案进行了复查,另外29例患者通过电话接受了关于生活质量的访谈。由于在放射科-肾内科联合会议上判定为高风险,34例患者未进行PTA。
接受PTA治疗的动脉硬化性肾血管疾病患者的5年生存率为83%,纤维肌性血管疾病患者为100%,未接受PTA治疗的患者为47%。两组的主要死亡原因均为心血管和脑血管事件。接受PTA治疗的患者血压降低,降压药物治疗需求减少。肾功能稳定。大多数接受PTA治疗的患者表示他们有“不受限制”的体力活动,在随访调查中,分别有53%、67%和75%的患者将身体、心理和社会幸福感自评在五级量表上为4 - 5级(大多为良好和非常好)。未治疗的患者未接受访谈。
该研究表明,肾PTA术后5年生存率高,血压控制改善,肾功能稳定,绝大多数患者对其身体、心理和社会幸福感评价良好。